

2024 Bioshares Biotech Summit - PROGRAM

Thursday 11 July

4.00pm - 6.00pm	Registration Open (Esplanade Hotel)
6.30pm	CEO Dinner (Biotech CEOs only), Republic of Fremantle
6.30pm	CFO Dinner (Contact: james.heath@microba.com)
6.30pm	Peasants Dinner (Contact: stuart.roberts@pittstreetresearch.com)

Sponsored by



Friday 12 July (Esplanade Hotel)

8.00am - 8.45am	Registration Open
9.00am	Introduction, Housekeeping
9.10am	Official Opening - Dr Jags Krishnam MLA , Parliamentary Secretary to the Premier, WA
9.20am	Australian Biotech Sector, Review & Outlook, Seth Lizee , Analyst, Euroz Hartleys

Session 1: New Opportunities Part 1

An overriding theme for this year's event is New Opportunities. With many companies in the sector having successfully developed their first product or product application, these sessions will look into the new market and product opportunities that are being targeted.

9.30am - 9.55am	Jon Pilcher, CEO of Neuren Pharmaceuticals
9.55am - 10.20am	James McBrayer, CEO of Cyclopharm
10.20am - 10.45am	John McCutcheon, CEO of EBR Systems
10.45am - 11.10am	James Agnew, CFO of Aroa Biosurgery
11.10am	WA Private Company Preview, Oncores Medical (Adam Wilkinson) Chair: Audrey Comparet, IQVIA
11.15am	Break

Sponsored by



Session 2: New Opportunities Part 2

The way that a target patient population is identified and accessed for a particular diagnostic or therapy is a rapidly evolving area. Whether that is through improved diagnostics, social media or with high visibility influencers, being able to reach the right patient, sometimes even before product approval, allows companies to gain market traction quickly. This session will explore this theme as well as new (additional) product opportunities that are being pursued.

12.00pm - 12.20pm	Brad O'Connor, CEO of Cogstate
12.20pm - 12.50pm	Lachlan Hay, Director of Global Operations, Clinuvel Pharmaceuticals
12.50pm - 1.10pm	Sara Lim, RoseRx
1.10pm	WA Private Company Preview

Sponsored by



1.15pm **Lunch**

2.10pm - 2.25pm	Stephen Earl, Acuity Capital
-----------------	-------------------------------------

Session 3: Drug Developers – Finding the Next Blockbuster Drug

Following on from Neuren's DAYBUE success, which Australian biotech is going to deliver the next blockbuster drug? A selection of the sector's leading drug developers will discuss aspects of their approach to achieving this goal, including partnering and the most clinical trial data.

2.25pm - 2.45pm	Nina Webster, CEO of Dimerix
2.45pm - 3.10pm	Kilian Kelly, CEO of Cynata Therapeutics
3.10pm - 3.30pm	Chris Burns, CEO of Amplia Therapeutics
3.30pm - 3.55pm	Rohan Hockings, CEO of PYC Therapeutics
3.55pm	WA Private Company Preview Chair: Andrew Stewart, Endpoints Capital

Sponsored by



4.00pm - 4.40pm **Break**

4.40pm - 5.10pm **The Mike Hirshorn Address**

Session 4: Repurposing Existing Pharmaceuticals

A short-cut to the 15 year drug development process is to identify a pharmaceutical that has been previously approved or developed by others, and repurposing that compound for a new indication. In these cases, the safety profile has already been well characterized, with evidence of efficacy being the main endpoint to secure regulatory approval.

5.10pm - 5.30pm	Paul MacLeman, Executive Chair of Island Pharmaceuticals
5.30pm - 5.50pm	Pete Smith, Executive Director of Race Oncology
5.50pm - 6.10pm	Paul Rennie, Founder & Chair of Paradigm Biopharmaceuticals

6.10pm **The Blake Award for Excellence ("The Blakey")**

6.20pm **End of Day 1**

7.30pm - 11.00pm	Cocktail Reception (Harbourside, Little Creatures Brewery, across from conference venue)
------------------	---

Sponsored by



Saturday 13 July

9.00am - 9.45am **Master Class: Prize or Prey? Preparing for M&A**

How do Boards and executives prepare for the possibility of a takeover? How do you behave when an offer arrives unannounced? How do you manage your directors' & officers' duties and navigate through continuous disclosure and insider trading regulation? These themes will be explored in this year's Master Class.

Coordinated by Piper Alderman

DAY 2 Sessions

Session 5: New Kids on the Block & Emerging Private Companies

Recently listed companies as well as private companies that will potentially list over the next 18 months will be featured in this session.

- 10.00am - 10.15am James Rowe, **ASX**
10.15am - 10.35am Henk-Jan Boele, CEO of **Blinklab**
10.35am - 10.55am Jason Carroll, CEO of **Tryptamine Therapeutics** (ExoPharm)
10.55am - 11.15am Ebru Davidson, GC, **Qbiotics Group**
11.15am - 11.35am Mary Beth Brinson, CEO of **Cyban**
11.35am - 11.55am Jeremy Chrisp, CEO of **Epixis**

Session 6: Diagnostics Part 1

Early diagnosis of disease continues to reduce the incidence of many terminal diseases. However changing global healthcare practices is challenging. This session will hear from two companies seeking to improve the early diagnosis of breast cancer and colorectal cancer.

- 11.55am - 12.15pm Jayne Shaw, Executive chair of **BCAL Diagnostics**
12.15pm **WA Private Company Preview**

12.20pm **Lunch**

Session 6: Diagnostics Part 2

- 1.20pm - 1.40pm David Atkins, CEO of **Rhythm Biosciences**

Session 7: Second Pass | Time for a Re-Assessment

Some familiar companies are presenting in this session, with most having re-directed their business plan, their disease focus or market application over the last decade. Their new products in development or new market applications for products may warrant a second pass to look at these stocks.

- 1.40pm - 2.00pm Michael Kotsanis, CEO of **Acrux**
2.00pm - 2.20pm Gary Phillips, CEO of **Syntara** (formerly Pharmaxis)
2.40pm - 3.00pm Simon Morriss, CEO of **Genetic Technologies**
3.00pm - 3.20pm Paul Anderson, CEO of **Orthocell**
3.20pm - 3.40pm Brent Barnes, CEO of **LBT Innovations**
3.40pm **WA Private Company Preview**
Chair: Tim Clark, Piper Alderman
3.45pm **Break**

Sponsored by



Session 8 – Three Different Ways to Treat Diseases

There are a number of approaches that have emerged over the years to tackle common diseases. From small molecule drugs which is the more traditional approach, to new immunotherapy using CAR T, and the most recent being to use the microbiome as a source to diagnose and also discover potential therapeutics. Each of these will be explored in this session.

- 4.30pm - 4.50pm Liz Dallimore, CEO of **Argenica**
4.50pm - 5.10pm Rebecca McQualter, COO of **Chimeric Therapeutics**
5.10pm - 5.30pm Luke Reid, CEO of **Microba Lifesciences**

Session 9 – Investment Panel

With the new wave of obesity treatment drugs expected to become a US\$150 billion global market, and a continuing raft of acquisitions, there is much to be optimistic about. Has positive sentiment returned to the global biotech sector? And if so how long will it last? What are the global trends in biotech?

And what are some of the best picks from Australia's leading biotech analysts and fund managers active in this sector are some of the topics that will be discussed in one of the favourite sessions of the Summit.

- 5.30pm - 6.00pm **Investment Panel**
Seth Lizee (analyst at Euroz Hartley) (TBC), Tanushree Jain (analyst at Petra Capital), Thomas Wakim (analyst at Bell Potter Securities), Madeleine Williams (Wilson HTM), Reece O'Connell (Merchant Funds) (TBC), Scott Power (senior analyst at Morgans)

Chair: Cameron Jones, Bio101

6.00pm **Closing Comments**

Sponsored by

Bio101.

- 7.00pm - late Conference Dinner (at Bread in Commons Restaurant, ticket required)

Sponsored by

